Cell Therapeutics, Inc. (CTIC) Reports Fourth Quarter and Full Year 2012 Financial Results
3/1/2013 7:30:52 AM
SEATTLE, Feb. 28, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2012.
"During the fourth quarter 2012, we began making PIXUVRI available to healthcare providers in the European Union and initiated commercial operations on a country-by-country basis," said James Bianco, M.D., President and CEO of CTI. "PIXUVRI is now available in eight countries in the E.U., and we are engaged in activities to increase awareness in the physician community of PIXUVRI's benefits for patients with multiply relapsed or refractory aggressive non-Hodgkin lymphoma.
comments powered by